NAPLS Omega-3 Fatty Acid Versus Placebo Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01429454 |
Recruitment Status :
Completed
First Posted : September 7, 2011
Results First Posted : May 19, 2020
Last Update Posted : May 19, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Psychosis | Drug: Omega-3 Long Chain Fatty Acid Drug: Placebo | Phase 1 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 127 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Randomized Double-Blind Trial of Omega 3 Fatty Acid Versus Placebo in Individuals at Risk for Psychosis |
Actual Study Start Date : | August 2011 |
Actual Primary Completion Date : | June 2016 |
Actual Study Completion Date : | June 2016 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: Soybean-Corn Blend Capsule
The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them.
|
Drug: Placebo
The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them. The dose will be 2 capsules per day. |
Experimental: Omega 3 long chain fatty acid
The Omega-3 Fatty Acid compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
|
Drug: Omega-3 Long Chain Fatty Acid
: The Omega-3FA compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
Other Name: Fish Oil, Ocean Nutrition |
- Rate of Conversion to Psychosis. [ Time Frame: 12 months ]The rate of conversion to psychosis among prodromal patients assigned at random to Omega-3 Fatty Acids at 12 months will be significantly lower than that among patients assigned to placebo.The Structured Interview for Prodromal Syndromes (SIPS) include the "Presence of Psychotic Syndrome (POPS)" scale that determines if the criteria for conversion to psychosis are met.
- Scale of Prodromal Symptoms (SOPS) Total Score (Indexing Severity of Positive, Negative, and General Symptoms) [ Time Frame: 6 month follow up ]
The reduction from baseline in the Scale of Prodromal Symptoms (SOPS) total score (indexing severity of positive, negative, and general symptoms) at 6 and 12 months will be significantly greater in prodromal patients assigned at random to Omega-3 Fatty Acids than in patients assigned to placebo.
Minimum SOPS score= 0 Maximum SOPS score= 114
Higher Total SOPS score does not necessarily mean the subject is more "psychotic" as the aggregate score is that of four independent categorically defined symptom subscales, including: Positive Symptoms Scale, Negative Symptoms Scale, Disorganized Symptoms Scale, and General Symptoms Scale. However, a higher Total SOPS score would likely indicate an individual is presenting with more overall symptoms.The Structured Interview for Prodromal Syndromes (SIPS) determines if the criteria for conversion to psychosis has been met.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years to 30 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects will be included if they are treatment-seeking patients between the ages of 12 and 30 who meet diagnostic criteria for a possible prodromal syndrome and are part of the ongoing NAPLS study.
Exclusion Criteria:
- use of antipsychotic medication in the previous month.
- concomitant medical or neurological illness.
- history of significant head injury.
- alcohol or drug abuse (excluding nicotine) in the past month or dependence in the past three months.
- screening full scale estimated IQ < 80.
- active suicidal or homicidal ideation.
- pregnancy or lactation.
- allergies to seafood or seafood related products or no history of seafood consumption

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01429454
United States, California | |
University of California, Los Angeles | |
Los Angeles, California, United States, 90095 | |
University of California, San Diego | |
San Diego, California, United States, 92093 | |
United States, Connecticut | |
Yale University | |
New Haven, Connecticut, United States, 06519 | |
United States, Georgia | |
Emory University | |
Atlanta, Georgia, United States, 30322 | |
United States, Massachusetts | |
Harvard | |
Boston, Massachusetts, United States, 02215 | |
United States, New York | |
Zucker Hillside Hospital | |
Glen Oaks, New York, United States, 11004 | |
United States, North Carolina | |
University of North Carolina | |
Chapel Hill, North Carolina, United States, 27599 | |
United States, Pennsylvania | |
VA Pittsburgh Healthcare System | |
Pittsburgh, Pennsylvania, United States, 15206 | |
Canada, Alberta | |
University of Calgary | |
Calgary, Alberta, Canada, T2N 1N4 |
Principal Investigator: | Kristin S Cadenhead, MD | UCSD |
Documents provided by Kristin Cadenhead, M.D., University of California, San Diego:
Responsible Party: | Kristin Cadenhead, M.D., Principal Investigator, University of California, San Diego |
ClinicalTrials.gov Identifier: | NCT01429454 |
Other Study ID Numbers: |
NAPLS- Omega3 U01MH081944 ( U.S. NIH Grant/Contract ) |
First Posted: | September 7, 2011 Key Record Dates |
Results First Posted: | May 19, 2020 |
Last Update Posted: | May 19, 2020 |
Last Verified: | May 2020 |
Prodromal Schizophrenia Psychosis Omega |
Psychotic Disorders Mental Disorders Schizophrenia Spectrum and Other Psychotic Disorders |